Jacobson & Schmitt Advisors LLC Takes $10.49 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Jacobson & Schmitt Advisors LLC purchased a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the first quarter, according to its most recent disclosure with the SEC. The firm purchased 24,987 shares of the company's stock, valued at approximately $10,493,000. IDEXX Laboratories makes up approximately 2.1% of Jacobson & Schmitt Advisors LLC's investment portfolio, making the stock its 24th biggest position.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. MorganRosel Wealth Management LLC purchased a new stake in shares of IDEXX Laboratories in the first quarter valued at $26,000. Hurley Capital LLC acquired a new position in IDEXX Laboratories during the fourth quarter worth $29,000. Colonial Trust Co SC increased its position in IDEXX Laboratories by 84.8% during the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after buying an additional 39 shares during the last quarter. Itau Unibanco Holding S.A. grew its position in shares of IDEXX Laboratories by 540.0% in the fourth quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock valued at $40,000 after purchasing an additional 81 shares during the last quarter. Finally, Cornerstone Planning Group LLC grew its position in shares of IDEXX Laboratories by 108.0% in the first quarter. Cornerstone Planning Group LLC now owns 104 shares of the company's stock valued at $44,000 after purchasing an additional 54 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Insider Activity at IDEXX Laboratories

In other news, Director M Anne Szostak sold 1,260 shares of the stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the transaction, the director owned 1,801 shares of the company's stock, valued at $922,724.34. This represents a 41.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.98% of the stock is owned by insiders.

Analyst Ratings Changes

IDXX has been the subject of several research reports. Wall Street Zen upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Saturday, July 12th. Stifel Nicolaus lifted their target price on shares of IDEXX Laboratories from $510.00 to $540.00 and gave the company a "hold" rating in a research note on Wednesday, July 2nd. Leerink Partners raised their price target on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a report on Thursday. Morgan Stanley lifted their target price on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a report on Monday, May 5th. Finally, Jefferies Financial Group started coverage on shares of IDEXX Laboratories in a report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 price target for the company. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $560.33.

IDEXX Laboratories Stock Performance

Shares of IDXX traded down $1.86 during trading hours on Thursday, hitting $518.71. The company's stock had a trading volume of 367,471 shares, compared to its average volume of 716,784. The company has a market cap of $41.72 billion, a price-to-earnings ratio of 47.94, a PEG ratio of 3.84 and a beta of 1.54. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.16 and a quick ratio of 0.81. The business has a 50 day simple moving average of $522.55 and a two-hundred day simple moving average of $461.26. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $549.52.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. The business had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. IDEXX Laboratories's revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.71 EPS. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.